Kezar Life Sciences (KZR)

Executive Summary

Kezar Life Sciences is a clinical-stage biotechnology company pioneering first-in-class small molecule therapies targeting protein homeostasis pathways for autoimmune diseases. Its lead asset, zetomipzomib (KZR-616), is a selective immunoproteasome inhibitor being developed for autoimmune hepatitis. In April 2025, Kezar completed the Phase 2 PORTOLA study (NCT05569759) evaluating zetomipzomib in autoimmune hepatitis, demonstrating a novel approach to immune modulation without broad immunosuppression. The company has a public listing (NASDAQ: KZR) and a market cap of approximately $54 million. Despite setbacks in other indications (lupus nephritis trial terminated, KZR-261 oncology program terminated), Kezar remains focused on autoimmune hepatitis, an area with significant unmet need. The upcoming catalysts center around advancing zetomipzomib into pivotal trials and potential partnership opportunities, which could drive significant value if successful.

Upcoming Catalysts (preview)

• Q3 2026Presentation of Phase 2 PORTOLA study results at a medical conference (e.g., AASLD)90% success
• H2 2026Initiation of Phase 3 trial for zetomipzomib in autoimmune hepatitis60% success
• TBDPotential partnership or licensing deal for zetomipzomib30% success